In what it describes as a significant step forward for India’s cancer treatment, India’s cell and gene therapy start-up Immuneel Therapeutics has launched Qartemi (varnimcabtagene autoleucel - IMN-003A), the country’s first global CAR T-cell therapy for adult B-cell on-Hodgkin lymphoma (B-NHL).
Immuneel pointed out that this personalized therapy for adult patients with relapsed or refractory B-NHL, addresses a critical gap in India’s cancer immunotherapy landscape. This ground-breaking therapy - benchmarked to global standards - is now available locally, offering renewed hope to patients for whom conventional therapies including chemotherapy prove ineffective.
India faces a rising burden of blood cancers, with around 120,000 new cases and over 70,000 deaths annually from leukemia, lymphoma, and multiple myeloma. Amidst the increasing incidence of blood cancer cases, Qartemi stands as a lifeline, representing the need for advanced treatment in CAR-T therapy becomes increasingly critical, the company said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze